Response curves have continued to climb for as long as patients are followed, allowing many with disappointing early results to catch up, according to data presented at the AAD meeting.
SAN DIEGO — In patients with alopecia areata , the decision of when to give up on JAK inhibitors because of an inadequate response is being complicated by long-term follow-up showing that some patients accrue hair very slowly, according to late breaker data presented at the annual meeting of the American Academy of Dermatology.
In the as-observed responses over time, the trajectory of response continued to climb through 76 weeks of follow-up in all three groups. Basically,"those with a SALT score of 94 did just as well as those with a SALT score of 51 when followed long-term," he said, noting that this was among several findings that confounded expectations.
To clarify this observation, Dr Sinclair made an analogy between acute and chronic urticaria. Chronicity appears to change the pathophysiology of both urticaria and AA, making durable remissions more difficult to achieve if the inflammatory response was persistently upregulated, he said. In the context of late breaking 68-week data with deuruxolitinib, an oral JAK inhibitor currently under FDA review for treating moderate to severe AA, presented in the same AAD session as Dr Sinclair's baricitinib data,, associate professor of dermatology, Yale University, New Haven, Connecticut, described similar long-term response curves. At 24 weeks, the SALT ≤ 20 response was achieved in 34.9% of patients, but climbed to 62.8% with continuous therapy over 68 weeks.
Hair Hair Growth Alopecia Areata Chronic Urticaria Urticaria Hives Urticaria And Angioedema Urticaria And Angio-Oedema Connecticut Remission
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Long-term follow-up shows slow hair regrowth in some patients with alopecia areataLate breaker data presented at the annual meeting of the American Academy of Dermatology reveals that some patients with alopecia areata (AA) experience slow hair regrowth, complicating the decision of when to stop JAK inhibitors due to inadequate response. Despite disappointing early results, many patients catch up and achieve complete hair regrowth after several years of treatment.
Read more »
Study Finds High TIL Levels Associated with Better Prognosis for Breast Cancer PatientsA recent study published in the Journal of the American Medical Association has found that breast cancer patients with high levels of tumor-infiltrating lymphocytes (TILs) have a better prognosis. The study aimed to explore whether patients with a favorable prognosis can avoid intensive chemotherapy regimens. Researchers followed patients for an average of 18 years and found that five years after surgery, 95% of patients with high TIL levels were still alive, compared to 82% of patients with low TIL levels. The recurrence rate for breast cancer was also significantly lower among those with high TIL levels.
Read more »
Racial Disparities in Prescription of Clozapine for Schizophrenia PatientsA new study reveals that White patients with schizophrenia are more likely to receive a prescription for clozapine compared to Black patients, even after considering various factors. The study analyzed electronic health record data of 3160 adult patients and found that 51% of White patients received a clozapine prescription, while only 40% of Black patients did.
Read more »
Topical Vs Oral Minoxidil for Androgenetic Alopecia: Which Option Is More Effective?Efficacy and safety of the two formulations were directly compared in a randomized, controlled, double-blind study of men with AGA conducted in Brazil.
Read more »
Review Describes Skin Effects Associated With SemaglutideAlopecia, dysesthesia, and other types of skin sensations have been reported in patients treated with semaglutide, but more research is needed to understand skin findings associated with this drug.
Read more »
ALS drug will be pulled from US market after study showed patients didn't benefitThe maker of a drug for Lou Gehrig’s disease that recently failed in a study says it will pull the medicine from the U.S. market.
Read more »